Rani Therapeutics Files 8-K on Key Agreements and Sales
Ticker: RANI · Form: 8-K · Filed: Oct 17, 2025 · CIK: 1856725
| Field | Detail |
|---|---|
| Company | Rani Therapeutics Holdings, Inc. (RANI) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001, $0.48, $0.605, $0.125, $0.4799 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
RANI filed an 8-K detailing new material agreements and equity sales.
AI Summary
Rani Therapeutics Holdings, Inc. filed an 8-K on October 17, 2025, reporting on events occurring on October 16, 2025. The filing indicates the entry into a material definitive agreement, the creation of a direct financial obligation, and unregistered sales of equity securities. Specific details regarding the nature of these agreements and sales were not provided in the excerpt.
Why It Matters
This 8-K filing signals significant corporate actions by Rani Therapeutics, potentially impacting its financial obligations and equity structure.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, financial obligations, and equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Rani Therapeutics Holdings, Inc. (company) — Registrant
- October 16, 2025 (date) — Date of earliest event reported
- October 17, 2025 (date) — Filing date
- 2051 Ringwood Avenue San Jose, California 95131 (address) — Principal Executive Offices
- (408) 457-3700 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Rani Therapeutics?
The provided excerpt does not specify the details of the material definitive agreement.
What are the terms of the direct financial obligation created by Rani Therapeutics?
The excerpt does not provide specific terms for the direct financial obligation.
What were the details of the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities, but specific details are not included in this excerpt.
What is the primary business of Rani Therapeutics Holdings, Inc.?
Rani Therapeutics Holdings, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
When was Rani Therapeutics Holdings, Inc. incorporated and in which state?
Rani Therapeutics Holdings, Inc. was incorporated in Delaware.
Filing Stats: 2,094 words · 8 min read · ~7 pages · Grade level 13.3 · Accepted 2025-10-17 07:38:15
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value RANI The Nasdaq Stock Mar
- $0.48 — hares to the Institutional Investors is $0.48 per share; and the Purchase Price of th
- $0.605 — he Shares to the Affiliated Investor is $0.605 per share, which reflects the consolida
- $0.125 — ported on the Nasdaq Stock Market, plus $0.125 per Common Warrant. The purchase price
- $0.4799 — re-Funded Warrants to the Purchasers is $0.4799 per Pre-Funded Warrant, which equals th
- $60.3 m — sing") are expected to be approximately $60.3 million, before deducting placement agent
- $45.0 million — in an aggregate principal amount up to $45.0 million. On October 16, 2025, the Company, Ra
- $6.0 million — suant to which Avenue agreed to convert $6.0 million of outstanding Loans into 12,500,000 Sh
- $10.0 million — er the Agreement, Rani LLC will receive $10.0 million up front and is eligible to receive up
- $18.0 million — front and is eligible to receive up to $18.0 million in technology transfer milestones, up t
- $57.0 million — n technology transfer milestones, up to $57.0 million in development milestones, up to $100.0
- $100.0 million — illion in development milestones, up to $100.0 million in a series of sales-based milestones,
Filing Documents
- d38236d8k.htm (8-K) — 41KB
- d38236dex101.htm (EX-10.1) — 222KB
- d38236dex102.htm (EX-10.2) — 129KB
- d38236dex103.htm (EX-10.3) — 90KB
- d38236dex104.htm (EX-10.4) — 79KB
- 0001193125-25-241963.txt ( ) — 816KB
- rani-20251016.xsd (EX-101.SCH) — 3KB
- rani-20251016_lab.xml (EX-101.LAB) — 18KB
- rani-20251016_pre.xml (EX-101.PRE) — 11KB
- d38236d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 17, 2025 Rani Therapeutics Holdings, Inc. By: / S / S VAI S ANFORD Name: Svai Sanford Title: Chief Financial Officer